From Liver Fibrosis to Hepatocarcinogenesis: Role of Excessive Liver HO and Targeting Nanotherapeutics
Overview
Authors
Affiliations
Liver fibrosis and hepatocellular carcinoma (HCC) have been worldwide threats nowadays. Liver fibrosis is reversible in early stages but will develop precancerosis of HCC in cirrhotic stage. In pathological liver, excessive HO is generated and accumulated, which impacts the functionality of hepatocytes, Kupffer cells (KCs) and hepatic stellate cells (HSCs), leading to genesis of fibrosis and HCC. HO accumulation is associated with overproduction of superoxide anion (O ) and abolished antioxidant enzyme systems. Plenty of therapeutics focused on HO have shown satisfactory effects against liver fibrosis or HCC in different ways. This review summarized the reasons of liver HO accumulation, and the role of HO in genesis of liver fibrosis and HCC. Additionally, nanotherapeutics targeting HO were summarized for further consideration of antifibrotic or antitumor therapy.
Asif M, Sohaib M, Anwaar W, Ahmed A, Khalid N, Tariq H Cureus. 2024; 16(11):e72892.
PMID: 39624533 PMC: 11611420. DOI: 10.7759/cureus.72892.
Zhang X, Yi X, Gao X, Li Y, Shen X Foods. 2024; 13(15).
PMID: 39123655 PMC: 11311329. DOI: 10.3390/foods13152464.
Khalifa Z, Abo Oura M, Hathoot A, Azzem M R Soc Open Sci. 2024; 11(6):231894.
PMID: 39100189 PMC: 11296075. DOI: 10.1098/rsos.231894.
Endothelial RUNX3 controls LSEC dysfunction and angiocrine LRG1 signaling to prevent liver fibrosis.
Ojha U, Kim S, Rhee C, You J, Choi Y, Yoon S Hepatology. 2024; .
PMID: 39042837 PMC: 11902585. DOI: 10.1097/HEP.0000000000001018.
Smart Microneedle Arrays Integrating Cell-Free Therapy and Nanocatalysis to Treat Liver Fibrosis.
Xu Y, Zhang Y, Tian H, Zhong Q, Yi K, Li F Adv Sci (Weinh). 2024; 11(31):e2309940.
PMID: 38874114 PMC: 11336984. DOI: 10.1002/advs.202309940.